METHODS: RESULTS: The majority of the patients (142, 74.7%) underwent hysteroscopic rollerball
endometrial ablation during the early proliferative phase of the menstrual cycle. The rest were operated on after
GnRH agonist pretreatment for 6-8 weeks. Ablations were successfully performed on all patients in a
day surgery setting. The average operation time was 36.3 ± 7.1 min. The mean
glycine deficit was 583.4 ± 247.3 mL. The ablation in the no-pretreatment group took a significantly longer time and had more
glycine absorption compared to the
GnRH agonist pretreatment group (P < 0.0001). Mean postoperative follow-up duration was five years (range 1-10 years). A total of 187 patients (98.4%) who had undergone hysteroscopic
endometrial ablation reported decreased
bleeding:
amenorrhea in 58 (30.5%),
hypomenorrhea in 78 (41.1%), and eumenorrhea in 51 (26.8%) patients. Three patients (1.6%) underwent
hysterectomy due to symptoms recurrence. A total of 165 (86.8%) patients with
dysmenorrhea reported either reduced or no
dysmenorrhea. There was no significant difference in the efficacy of hysteroscopic rollerball
endometrial ablation between patients who underwent pretreatment with
GnRH agonists and those who did not. No major complications related to the procedure were reported.
CONCLUSIONS: